Key statistics
Previous close$98.83
Open$99.90
Day high$102.13
Day low$99.47
52-week high$137.49
52-week low$81.97
Market cap175.35B
Volume17.06M
Average volume13.37M
P/E ratio19.32
Forward P/E14.84
EPS5.21
Dividend yield+2.46%
Market context
Why it moved
Abbott Laboratories (ABT) rose after the company reported quarterly earnings that beat EPS expectations, delivered strong double-digit revenue growth year over year, and raised its guidance for both Q3 and full-year 2026, prompting analysts including Piper Sandler to reiterate bullish ratings and lift their price targets.
What is happening
Recent company-specific developments and publisher coverage.
July 18, 2026Abbott Laboratories closed modestly higher, extending Thursday's powerful post-earnings rally as Wall Street analysts raised price targets following a blowout Q2 report. The company posted adjusted EPS of $1.31 (vs. $1.28 est.) on revenue of $12.59B (+13% YoY), with diagnostics surging 42% — its first beat in six quarters — fueled by the Exact Sciences acquisition. Abbott raised full-year EPS guidance to $5.45–$5.60 and alleviated fears around ACA subsidy cuts, Exact Sciences integration risk, and MedTech procedure volumes. JP Morgan raised its target to $120, BTIG to $134, RBC reiterated Outperform at $130, and Wells Fargo lifted to $112, with the average analyst target near $118.1.8618
July 17, 2026Abbott Laboratories surged over 10% — its best single-day gain in more than 24 years — after reporting Q2 adjusted EPS of $1.31, beating the $1.28 consensus, on revenue of $12.59 billion that topped estimates by ~$70 million. The standout was diagnostics, which surged 42% year-over-year to $3.09 billion — its first beat in six quarters — driven by the recently closed Exact Sciences acquisition adding Cologuard and Oncotype DX to Abbott's portfolio. Medical devices grew 9% to $5.85 billion, with electrophysiology, rhythm management, and diabetes care (FreeStyle Libre +11%) all delivering strong results. Abbott raised its full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, with CEO Robert Ford citing accelerating momentum into the second half. The rally was amplified by deeply depressed valuations — shares had fallen ~30% YTD ahead of the print amid litigation overhang tied to infant formula NEC claims and competitive concerns in CGM — making the beat a meaningful sentiment reset. Wells Fargo raised its price target to $112 from $109, and the stock closed as the top performer in the S&P 500, though shares remain roughly 30% below their 2021 peak.10.6979
July 16, 2026Abbott Laboratories closed modestly higher, edging up after a sharp 3.4% decline the prior session driven by NEC litigation fears, HCA's reduced surgical volume outlook, and broader MedTech sector weakness. Investor focus is squarely on Q2 earnings due July 16, with analysts projecting 1.6% EPS growth to $1.28 and ~12% revenue growth to $12.48B, boosted by the Exact Sciences acquisition. Despite the recovery, lingering headwinds remain: ongoing Similac NEC tort liability, Nutrition segment revenue expected to decline ~4%, and an 11% stock drop over the prior three months. UBS highlighted healthcare as a key allocation focus amid improving earnings revisions, offering some sector tailwind heading into results.0.3485
July 15, 2026Abbott Laboratories fell sharply ahead of its Q2 2026 earnings report due Thursday, July 16, underperforming both the healthcare sector ETF (XLV) and the broader S&P 500, which closed modestly higher on a soft CPI print. Investor sentiment was pressured by renewed concerns over escalating NEC tort liability tied to its Similac infant formula, with bellwether trials approaching and a recent $60M verdict against a competitor raising fears of significant punitive damages. Competitive headwinds facing the FreeStyle Libre CGM franchise also weighed on sentiment, even as analysts maintain a median price target of $121 — well above current levels.-3.4144
July 14, 2026Abbott Laboratories closed nearly 2% lower amid broad market weakness driven by renewed U.S.-Iran military tensions that sent oil prices surging and rattled equities. The session comes ahead of a high-stakes Q2 earnings report due Thursday, July 16, where investors will scrutinize device and diagnostics sales and margins — particularly FreeStyle Libre growth and the integration impact of Exact Sciences. Analyst sentiment remains constructive, with Baird initiating coverage at Outperform on July 13 and Wells Fargo maintaining a Buy with a $109 target, while the stock trades roughly 23% lower year-to-date and screens as undervalued on multiple metrics including a DCF estimate of ~$148 per share.-1.9323
July 11, 2026Abbott Laboratories closed modestly lower, edging down as investors look ahead to its Q2 2026 earnings report scheduled for July 16, with options markets pricing in a potential 4.5% move on the release. Analyst sentiment remains cautiously constructive — Wells Fargo reiterated its Buy rating with a $109 target, while Evercore ISI trimmed its target to $112 but maintained Outperform, citing healthy procedure volumes across MedTech. Despite a steep year-to-date decline of roughly 23%, the stock has seen a short-term rebound of over 5% in the past 30 days, with the consensus analyst target of ~$116 suggesting significant upside if Q2 results and full-year guidance can rebuild investor confidence.-0.4979
July 10, 2026Abbott Laboratories closed modestly lower, slipping alongside the broader healthcare sector (XLV) as renewed U.S.-Iran geopolitical tensions rattled equity markets and reignited inflation concerns. With Q2 earnings due July 16 — where options markets imply a ~4.5% move — investor attention is sharpening around Abbott's FreeStyle Libre CGM franchise and full-year guidance amid a meaningful year-to-date decline of roughly 23%. Evercore ISI recently trimmed its price target to $112 (from $120) while maintaining an Outperform rating, citing generally healthy medtech procedure volumes, and analyst consensus sits at $116.54 — reflecting a notable discount to the current price.-0.8195
July 9, 2026Abbott Laboratories edged lower alongside the broader healthcare sector as a risk-off mood gripped markets after President Trump declared the U.S.-Iran ceasefire 'over,' sending oil prices surging over 5% and stoking inflation fears. Despite the macro headwinds, Abbott remains a relative bright spot in healthcare: Q1 2026 revenue grew ~7.8% year-over-year to $11.2B, Baird recently reiterated an Outperform rating with a $121 target, and the company has seen positive catalysts including CE mark approval for its Volt pulsed field ablation system and a resolved regulatory probe. Healthcare has been the S&P 500's top-performing sector over the past two weeks, with XLV up over 13% in that span, though the sector pulled back modestly on Wednesday alongside the broader market selloff.-0.6886
Barron's · July 17, 2026Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years↗BleepingComputer · July 17, 2026Abbott probes two cyber incidents amid extortion claims↗MarketBeat · July 16, 2026Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street↗Investor's Business Daily · July 16, 2026Abbott Surges 11% After Boosting 2026 Profit Outlook↗Bloomberg.com · July 16, 2026Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise↗WSJ · July 16, 2026Abbott Laboratories Sales Rise on Diagnostics Growth↗PR Newswire · July 16, 2026Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance↗Seeking Alpha · July 15, 2026Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition↗ Benzinga · July 17, 2026Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112Benzinga · July 17, 2026Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118Mt Newswire · July 17, 2026Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC SaysBenzinga · July 17, 2026JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120Benzinga · July 17, 2026Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112Benzinga · July 17, 2026These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 ResultsBenzinga · July 17, 2026RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $130 Price TargetMt Newswire · July 17, 2026JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating
